Scioderm, a Durham, North Carolina-based company developing dermatology therapeutics, has raised $16 million in Series A funding led by Morgenthaler Ventures, with Technology Partners filling out the rest of the round.

MuleSoft, which provides enterprises with a cloud-based platform to integrate its mobile and on-premise data and applications, has raised $37 million in new funding. New Enterprise Associates lead the round, with participation from Salesforce.com, as well as returning investors Hummer Winblad Venture Partners, Morgenthaler Ventures, Lightspeed Venture Partners, SAP Ventures and Bay Partners. The company has now raised about $81 million in capital since 2006.

Morgenthaler Ventures has begun the initial steps of looking to raise its 10th fund, an IT-focused, early stage fund with a hard cap of $200 million, according to an LP source familiar with the fundraising effort.

IT business Beyond Lucid Technologies has received a six-figure convertible note from Dalmore Investments, an angel fund based in Minneapolis. The two organizations’ founders met in October at the DC to VC competition sponsored by Health 2.0 and Morgenthaler Ventures.

Principia Biopharma Inc., a biopharmaceutical company focused on immunology, autoimmune diseases, and oncology, has raised $12.5 million. Investors include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

Practice Fusion, which operates an electronic medical record platform for 150,000 medical providers, has raised a $34 million Series C round of funding led by Artis Ventures. Other investors in the round include Felicis Ventures, Band of Angels, Founders Fund, Morgenthaler Ventures and SV Angel. among other institutional and individual investors. The company says it has now raised $64 million in total funding since it was launched in 2007.

Promedior, a clinical stage biotechnology company developing biologic therapeutics for the treatment of fibrosis, has appointed Suzanne L. Bruhn as president and chief executive officer. In March, the company announced the closing of a Series D financing round led by Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare [...]

Relievant Medsystems Inc., a medical device company focused on basivertebral nerve ablation for the treatment of chronic axial low back pain, has raised $30 million in Series D financing. New Enterprise Associates led the financing with participation from existing investors Canaan Partners, Emergent Medical Partners, Morgenthaler Ventures and ONSET Ventures. The company is based in [...]

Promedior, a clinical stage biotechnology company has raised $21.5M in a first closing of a Series D financing round. The financing was led by a new investor, Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This [...]

Malvern, Penn.-based Promedior Inc., a clinical stage biotechnology company developing therapeutics for fibroproliferative diseases, has held a $21.5 million first closing of its Series D round.  New investor Fibrotec Ventures led the round, which included existing shareholders Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This new round [...]